Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia
MS Kostapanos, HJ Milionis, MS Elisaf - American journal of …, 2010 - Springer
HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia
MS Kostapanos, HJ Milionis… - American journal of …, 2010 - pubmed.ncbi.nlm.nih.gov
HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia
MS Kostapanos, HJ Milionis, MS Elisaf - American Journal of …, 2010 - infona.pl
HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
[引用][C] Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia
MS Kostapanos, HJ Milionis, MS Elisaf - 2010 - olympias.lib.uoi.gr
Repository of UOI "Olympias": Rosuvastatin-associated adverse effects and drug-drug interactions
in the clinical setting of dyslipidemia Skip navigation Home Browse Communities & Collections …
in the clinical setting of dyslipidemia Skip navigation Home Browse Communities & Collections …
Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia.
MS Kostapanos, HJ Milionis… - American Journal of …, 2010 - search.ebscohost.com
HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
MS Kostapanos, HJ Milionis… - American Journal of …, 2010 - europepmc.org
HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …